- Home
- JLS vs STRO Comparison
JLS vs STRO Comparison
Compare JLS & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | STRO |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.9M | 85.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | JLS | STRO |
|---|---|---|
| Price | $18.50 | $16.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 26.6K | ★ 131.7K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,646,000.00 |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.48 | $5.23 |
| 52 Week High | $17.97 | $21.25 |
Technical Indicators
Market Signals| Indicator | JLS | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 74.44 |
| Support Level | $18.12 | $14.08 |
| Resistance Level | $18.48 | $17.33 |
| Average True Range (ATR) | 0.15 | 1.47 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 93.18 | 89.28 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.